NCT05259085 - Study of ALXN2050 in Participants With Hepatic Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

August 12, 2024

Study Completion Date

August 12, 2024

Conditions

Impaired Hepatic FunctionHealthy

Interventions

DRUG

ALXN2050

ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.

Trial Locations (2)

32809

Research Site, Orlando

33014

Research Site, Hialeah